Cargando…
Drug discovery and development scheme for liver-targeting bridged nucleic acid antisense oligonucleotides
Antisense oligonucleotides (ASOs) containing bridged nucleic acids (BNAs) have been proven to be very powerful. However, ensuring a reliable discovery and translational development scheme for this class of ASOs with wider therapeutic windows remains a fundamental challenge. We here demonstrate the r...
Autores principales: | Wada, Fumito, Yamamoto, Tsuyoshi, Kobayashi, Tadayuki, Tachibana, Keisuke, Ito, Kosuke Ramon, Hamasaki, Mayumi, Kayaba, Yukina, Terada, Chisato, Yamayoshi, Asako, Obika, Satoshi, Harada-Shiba, Mariko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8560717/ https://www.ncbi.nlm.nih.gov/pubmed/34760338 http://dx.doi.org/10.1016/j.omtn.2021.10.008 |
Ejemplares similares
-
Highly Potent GalNAc-Conjugated Tiny LNA Anti-miRNA-122 Antisense Oligonucleotides
por: Yamamoto, Tsuyoshi, et al.
Publicado: (2021) -
Dynamic and static control of the off-target interactions of antisense oligonucleotides using toehold chemistry
por: Terada, Chisato, et al.
Publicado: (2023) -
Superior Silencing by 2′,4′-BNA(NC)-Based Short Antisense Oligonucleotides Compared to 2′,4′-BNA/LNA-Based Apolipoprotein B Antisense Inhibitors
por: Yamamoto, Tsuyoshi, et al.
Publicado: (2012) -
Development of Antisense Drugs for Dyslipidemia
por: Yamamoto, Tsuyoshi, et al.
Publicado: (2016) -
Antisense Oligonucleotides Targeting Y-Box Binding Protein-1 Inhibit Tumor Angiogenesis by Downregulating Bcl-xL-VEGFR2/-Tie Axes
por: Setoguchi, Kiyoko, et al.
Publicado: (2017)